Price to Sales (P/S)
since 2005
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Capital Asset Pricing Model (CAPM)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Regeneron Pharmaceuticals Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenues1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 5, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 8, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 8, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2007 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
- Share Price
- The share price exhibited a general upward trajectory over the observed period, with notable fluctuations. Starting at $16.37 in early 2006, it experienced a gradual increase until 2011, followed by a sharp rise peaking at $401.74 in 2015. Subsequent years showed volatility, with a decline to $322.62 in 2017, a recovery to $494.9 in 2021, and further increases reaching $936.33 in 2024. However, the most recent data point in 2025 indicates a decrease to $716.72, suggesting some price correction or market adjustment.
- Sales Per Share
- Sales per share generally increased throughout the period, reflecting expanding revenue relative to shares outstanding. From $1.16 in 2006, sales per share dipped slightly in 2007 then steadily increased, with significant growth from 2012 onward. The value surged from $14.15 in 2013 to a peak of $148.07 in 2022, before declining to $111.35 in 2023. A modest recovery is observed in 2024 and 2025, reaching $129.91. This trend denotes strong sales growth with occasional decreases likely due to market or operational factors.
- Price-to-Sales Ratio (P/S)
- The P/S ratio demonstrated considerable variability during the period. It started high at 14.06 in 2006, increased to nearly 20 in 2007, then dropped sharply to as low as 4.2 in 2022, reflecting substantial changes in valuation relative to sales figures. The ratio exhibited peaks and troughs, such as reaching 20.9 in 2012 and declining to 5.52 by 2025. These fluctuations suggest periods where market pricing diverged from sales performance, possibly influenced by investor sentiment, market conditions, or company fundamentals.
- Overall Analysis
- The company exhibited strong growth in sales per share over the 20-year span, particularly marked by rapid increases after 2010. Share price movements, while generally positive, demonstrated volatility and some periods of retracement after peaks. The P/S ratio's volatility indicates alternating market optimism and caution, with valuation multiples contracting despite growth in sales per share in some intervals. The recent decrease in share price alongside rebounds in sales per share suggests potential adjustments in market expectations or shifts in competitive dynamics.
Comparison to Competitors
Regeneron Pharmaceuticals Inc., P/S, long-term trends, comparison to competitors
| Regeneron Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2025 | ||||||||||||
| Feb 5, 2024 | ||||||||||||
| Feb 6, 2023 | ||||||||||||
| Feb 7, 2022 | ||||||||||||
| Feb 8, 2021 | ||||||||||||
| Feb 7, 2020 | ||||||||||||
| Feb 7, 2019 | ||||||||||||
| Feb 8, 2018 | ||||||||||||
| Feb 9, 2017 | ||||||||||||
| Feb 11, 2016 | ||||||||||||
| Feb 12, 2015 | ||||||||||||
| Feb 13, 2014 | ||||||||||||
| Feb 15, 2013 | ||||||||||||
| Feb 21, 2012 | ||||||||||||
| Feb 17, 2011 | ||||||||||||
| Feb 18, 2010 | ||||||||||||
| Feb 26, 2009 | ||||||||||||
| Feb 27, 2008 | ||||||||||||
| Mar 12, 2007 | ||||||||||||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Regeneron Pharmaceuticals Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Regeneron Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 5, 2025 | ||
| Feb 5, 2024 | ||
| Feb 6, 2023 | ||
| Feb 7, 2022 | ||
| Feb 8, 2021 | ||
| Feb 7, 2020 | ||
| Feb 7, 2019 | ||
| Feb 8, 2018 | ||
| Feb 9, 2017 | ||
| Feb 11, 2016 | ||
| Feb 12, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 21, 2012 | ||
| Feb 17, 2011 | ||
| Feb 18, 2010 | ||
| Feb 26, 2009 | ||
| Feb 27, 2008 | ||
| Mar 12, 2007 | ||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Regeneron Pharmaceuticals Inc., P/S, long-term trends, comparison to industry (health care)
| Regeneron Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 5, 2025 | ||
| Feb 5, 2024 | ||
| Feb 6, 2023 | ||
| Feb 7, 2022 | ||
| Feb 8, 2021 | ||
| Feb 7, 2020 | ||
| Feb 7, 2019 | ||
| Feb 8, 2018 | ||
| Feb 9, 2017 | ||
| Feb 11, 2016 | ||
| Feb 12, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 21, 2012 | ||
| Feb 17, 2011 | ||
| Feb 18, 2010 | ||
| Feb 26, 2009 | ||
| Feb 27, 2008 | ||
| Mar 12, 2007 | ||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).